Company: ENTXW
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001178913-25-002702
Chunk: 11

Company: Entera Bio Ltd.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 2
Chunk 11
---
 $
                
                  1,004

                  24
                
                %

                      Financial income, net

                $
                
                  (8

                  )

                $
                
                  (65

                  )

                $
                
                  57

                  (88

                  )%

                  Net loss

                  $

                  5,223

                  $

                  4,162

                  $

                  1,061

                  25
                
                %

            25

Revenues

Revenues for the six months ended June 30, 2025 and 2024 were $42 thousand and $57 thousand, respectively, which were attributable to research services we provided pursuant to the research services agreement. The Company completed the first stage of its obligations under the research services agreement in the first quarter of 2025.

Cost of Revenues

Cost of revenues for the six months ended June 30, 2025 and 2024 was $42 thousand and $48 thousand, respectively, which was attributable to research services we provided pursuant to the research services agreement. The Company completed the first stage of its obligations under the research services agreement in the first quarter of 2025.

Research and Development Expenses

Research and development expenses for six months ended June 30, 2025 were $2.6 million as compared to $1.8 million for the six months ended June 30, 2024. The increase of $0.8 million was primarily due to an increase of $0.6 million in other consulting fees, including regulatory required in connection with filing of a type A meeting and ongoing optimization processes related to the preparation of the EB613 phase 3 program and $0.2 million in connection with our internal programs and collaboration programs.

General and Administrative Expenses

General and administrative expenses for the six months ended June 30, 2025 were $2.6 million as compared to $2.4 million for the six months ended June 30, 2024. The increase was primarily due to an increase of $0.2 million in legal expenses related to the OPKO collaboration agreement and other potential strategic agreements. 

Financial Income, Net

Financial income, net for the six months ended June 30, 2025 and 2024 was $8 thousand and $65 thousand, respectively. Our financial income was composed mainly of interest income from bank deposits and exchange rate differences of certain currencies against our functional currency, which is the U.S. Dollar.

Liquidity and Capital Resources

Since inception, we have incurred significant